Predicting Survival for Patients With Metastatic Disease.

Autor: Benson KRK; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Aggarwal S; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Carter JN; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., von Eyben R; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Pradhan P; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Prionas ND; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Bui JL; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Soltys SG; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Hancock S; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Gensheimer MF; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California., Koong AC; Radiation Oncology Department, MD Anderson Cancer Center, Houston, Texas., Chang DT; Radiation Oncology Department, Stanford Cancer Institute, Stanford, California. Electronic address: dtchang@stanford.edu.

Publikováno v: International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2020 Jan 01; Vol. 106 (1), pp. 52-60. Date of Electronic Publication: 2019 Nov 01.

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.

Autor: Yurgelun MB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. matthew_yurgelun@dfci.harvard.edu.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA. matthew_yurgelun@dfci.harvard.edu., Chittenden AB; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Morales-Oyarvide V; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Rubinson DA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA., Dunne RF; Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Kozak MM; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA., Qian ZR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Welch MW; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Brais LK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA., Da Silva A; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Bui JL; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA., Yuan C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA., Li T; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Li W; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Masuda A; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Gu M; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA., Bullock AJ; Department of Medicine, Division of Hematology/Oncology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA., Chang DT; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA., Clancy TE; Department of Surgery, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Linehan DC; Department of Surgery, University of Rochester Medical Center, Rochester, NY, USA., Findeis-Hosey JJ; Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA., Doyle LA; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA., Ducar MD; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA., Wollison BM; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA., Khalaf N; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA., Perez K; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA., Syngal S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA., Aguirre AJ; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA., Hahn WC; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA., Meyerson ML; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.; Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, MA, USA.; Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA, USA., Fuchs CS; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.; Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA., Ogino S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Hornick JL; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Hezel AF; Department of Medicine, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA., Koong AC; Department of Radiation Oncology, Stanford Cancer Institute, Stanford, CA, USA.; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nowak JA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA., Wolpin BM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.; Department of Medicine, Brigham & Women's Hospital, Boston, MA, USA.

Publikováno v: Genetics in medicine : official journal of the American College of Medical Genetics [Genet Med] 2019 Jan; Vol. 21 (1), pp. 213-223. Date of Electronic Publication: 2018 Jul 02.

A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence.

Autor: Heumann, Thatcher R.¹ (AUTHOR), Baretti, Marina¹ (AUTHOR), Sugar, Elizabeth A.^1,2 (AUTHOR), Durham, Jennifer N.¹ (AUTHOR), Linden, Sheila¹ (AUTHOR), Lopez-Vidal, Tamara Y.¹ (AUTHOR), Leatherman, James¹ (AUTHOR), Cope, Leslie¹ (AUTHOR), Sharma, Anup^1,3 (AUTHOR), Weekes, Colin D.⁴ (AUTHOR), O'Dwyer, Peter J.⁵ (AUTHOR), Reiss, Kim A.⁵ (AUTHOR), Monga, Dulabh K.⁶ (AUTHOR), Ahuja, Nita^1,3 (AUTHOR), Azad, Nilofer S.¹ (AUTHOR) Nazad2@jhmi.edu

Publikováno v: Clinical Epigenetics. 12/3/2022, Vol. 14 Issue 1, p1-11. 11p.

KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients.

Autor: Lavacchi, Daniele, Polvani, Simone, Taddei, Antonio, Scolari, Federico, Messerini, Luca, Caliman, Enrico, Moraldi, Luca, Guidolin, Alessia, Grazi, Gian Luca, Galli, Andrea, Pillozzi, Serena, Antonuzzo, Lorenzo

Publikováno v: Frontiers in Oncology; 2023, p1-12, 12p

Reevaluation of regional lymph nodes in patients with pancreatic ductal adenocarcinoma in the pancreatic body and tail.

Autor: Matsui, Yuki, Hashimoto, Daisuke, Satoi, Sohei, Yamamoto, Tomohisa, Yamaki, So, Ishida, Mitsuaki, Hirooka, Satoshi, Ikeura, Tsukasa, Sekimoto, Mitsugu

Publikováno v: Annals of Gastroenterological Surgery; Jan2023, Vol. 7 Issue 1, p147-156, 10p